Skip to main content
    Q

    Q32 Bio Inc (QTTB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.29
    -0.42 (-4.82%)

    Market Cap: $260.64M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Q32 Bio Inc (QTTB) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Q32 Bio (QTTB) trades at 2.5x trailing earnings and 5.2x sales. Its price to book ratio is 1.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)2.5x
    Forward P/EN/A
    Price to sales5.2x
    Price to book1.0x
    PEGN/A
    As of Nov 17, 2026

    Valuation History

    Over the 5 of the 8 year ends shown that have a P/S, its P/S ranged from 0.8x in 2025 to 528.7x in 2019. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$3.321.4x0.8x1.0x
    2024$3.44N/AN/A7.4x
    2023$10.94N/AN/AN/A
    2022$22.66N/A22.5x0.4x
    2021$65.47N/A5.5x1.0x
    2020$203.06N/A193.0x3.0x
    2019$372.30N/A528.7x3.5x
    2018$402.16N/AN/A3.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About QTTB

    Is QTTB stock overvalued?

    GNG's valuation label for QTTB is Overvalued.

    What is QTTB's price to sales ratio?

    Q32 Bio has a price to sales ratio of 5.2x.